Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

被引：0
|
作者：
Shuang Wang
Yun Peng
Rongjuan Wang
Shasha Jiao
Min Wang
Weijin Huang
Chao Shan
Wen Jiang
Zepeng Li
Chunying Gu
Ben Chen
Xue Hu
Yanfeng Yao
Juan Min
Huajun Zhang
Ying Chen
Ge Gao
Peipei Tang
Gang Li
An Wang
Lan Wang
Jinchao Zhang
Shuo Chen
Xun Gui
Zhiming Yuan
Datao Liu
机构：
[1] Mabwell (Shanghai) Bioscience Co.,Center for Biosafety Mega
[2] Ltd,Science, Wuhan Institute of Virology
[3] Beijing Kohnoor Science & Technology Co.,Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products
[4] Ltd,State Key Laboratory of Virology, Wuhan Institute of Virology
[5] Chinese Academy of Sciences,Wuhan Institute of Virology
[6] National Institutes for Food and Drug Control,Ludwig Cancer Research, Nuffield Department of Medicine
[7] Chinese Academy of Sciences,undefined
[8] Chinese Academy of Sciences,undefined
[9] University of Oxford,undefined
来源：
Nature Communications | / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with FcγRIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19.
引用
收藏
相关论文
共 50 条
  • [1] Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
    Wang, Shuang
    Peng, Yun
    Wang, Rongjuan
    Jiao, Shasha
    Wang, Min
    Huang, Weijin
    Shan, Chao
    Jiang, Wen
    Li, Zepeng
    Gu, Chunying
    Chen, Ben
    Hu, Xue
    Yao, Yanfeng
    Min, Juan
    Zhang, Huajun
    Chen, Ying
    Gao, Ge
    Tang, Peipei
    Li, Gang
    Wang, An
    Wang, Lan
    Zhang, Jinchao
    Chen, Shuo
    Gui, Xun
    Yuan, Zhiming
    Liu, Datao
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [2] Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants
    Zakir, Tasnim Saifudin
    Meng, Tao
    Carmen, Lee Ching Pei
    Chu, Justin Jang Hann
    Lin, Raymond Tzer Pin
    Prabakaran, Mookkan
    VIRUSES-BASEL, 2022, 14 (02):
  • [3] Characterization of therapeutic antibody efficacy against multiple SARS-CoV-2 variants in the hamster model
    Cong, Yu
    Dixit, Saurabh
    Perry, Donna L.
    Huzella, Louis M.
    Kollins, Erin
    Byrum, Russell
    Anthony, Scott M.
    Drawbaugh, David
    Lembirik, Sanae
    Postnikova, Elena
    Eaton, Brett
    Murphy, Michael
    Kocher, Gregory
    Hadley, Kyra
    Marketon, Anthony E.
    Bernbaum, Rebecca M.
    Hischak, Amanda M. W.
    Hart, Randy
    Vaughan, Nick
    Wada, Jiro
    Qin, Jing
    St Claire, Marisa C.
    Schmaljohn, Connie S.
    Holbrook, Michael R.
    ANTIVIRAL RESEARCH, 2024, 230
  • [4] Engineered Therapeutic Antibody Against SARS-CoV-2
    Monrat Chulanetra
    Current Clinical Microbiology Reports, 2023, 10 : 222 - 235
  • [5] Engineered Therapeutic Antibody Against SARS-CoV-2
    Chulanetra, Monrat
    CURRENT CLINICAL MICROBIOLOGY REPORTS, 2023, 10 (04) : 222 - 235
  • [6] SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
    Barnes, Christopher O.
    Jette, Claudia A.
    Abernathy, Morgan E.
    Dam, Kim-Marie A.
    Esswein, Shannon R.
    Gristick, Harry B.
    Malyutin, Andrey G.
    Sharaf, Naima G.
    Huey-Tubman, Kathryn E.
    Lee, Yu E.
    Robbiani, Davide F.
    Nussenzweig, Michel C.
    West, Anthony P., Jr.
    Bjorkman, Pamela J.
    NATURE, 2020, 588 (7839) : 682 - +
  • [7] SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
    Christopher O. Barnes
    Claudia A. Jette
    Morgan E. Abernathy
    Kim-Marie A. Dam
    Shannon R. Esswein
    Harry B. Gristick
    Andrey G. Malyutin
    Naima G. Sharaf
    Kathryn E. Huey-Tubman
    Yu E. Lee
    Davide F. Robbiani
    Michel C. Nussenzweig
    Anthony P. West
    Pamela J. Bjorkman
    Nature, 2020, 588 : 682 - 687
  • [8] Characterization of the neutralizing antibody response in SARS-CoV-2 infected individuals
    Mamede, J.
    Ash, M.
    Gambut, S.
    Melani, R.
    Dharan, A.
    Tarhoni, I.
    Fhied, C.
    Goo, Y. Ah
    Campbell, E.
    Al-Harthi, L.
    Kelleher, N.
    Borgia, J.
    Schneider, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24
  • [9] Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2
    Deepthi, Varughese
    Mohanakumar, Kochupurackal P.
    Rajamma, Usha
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (07): : 2911 - 2925
  • [10] Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys
    Jilei Jia
    Zhaojuan Yin
    Xiao Zhang
    Huimin Li
    Dan Meng
    Qianqian Liu
    Hongfang Wang
    Meng Han
    Shixiang Suo
    Yan Liu
    Ping Hu
    Chunyun Sun
    Jing Li
    Liangzhi Xie
    Pharmaceutical Research, 2022, 39 : 2191 - 2201
12345